Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM027542-005
Application #
3610109
Study Section
Project Start
1982-04-01
Project End
1985-07-01
Budget Start
1985-04-01
Budget End
1985-07-01
Support Year
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Weiss, G R; Kuhn, J G; Rizzo, J et al. (1995) A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemother Pharmacol 35:397-402
Ravdin, P M; Havlin, K A; Marshall, M V et al. (1991) A phase I clinical and pharmacokinetic trial of hepsulfam. Cancer Res 51:6268-72
Slichenmyer, W J; Von Hoff, D D (1991) Taxol: a new and effective anti-cancer drug. Anticancer Drugs 2:519-30
Kuhn, J G; Von Hoff, D D; Hersh, M et al. (1989) Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion. Eur J Cancer Clin Oncol 25:797-803
Hersh, M R; Kuhn, J G; Phillips, J L et al. (1986) Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol 17:277-80
Hutton, J J; Von Hoff, D D (1986) Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay. Cancer Drug Deliv 3:115-22
Hersh, M R; Linn, W; Kuhn, J G et al. (1986) Electrocardiographic monitoring of patients receiving phase I cancer chemotherapy. Cancer Treat Rep 70:349-52
Dorr, F A; Von Hoff, D D; Kuhn, J G et al. (1986) Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic. Cancer Res 46:2562-5
Melink, T J; Von Hoff, D D; Kuhn, J G et al. (1985) Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res 45:2859-65
Weiss, G R; Hersh, M; Kuhn, J G et al. (1985) A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer. Cancer Chemother Pharmacol 15:144-8